Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658311 | 0.90 | SMN1; SMN2 (0.43) | HPGDHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL18885626 | 0.89 | SMN1; SMN2 (0.42) | HPGDHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL19643024 | 0.88 | SMN1; SMN2 (0.41) | HPGDHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL8191582 | 0.87 | HPGD (0.36) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL15744056 | 0.86 | SMN1; SMN2 (0.38) | HPGDHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL17145176 | 0.86 | HPGD (0.40) | HPGDHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL16453924 | 0.86 | HPGD (0.38) | HPGDHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL16574886 | 0.86 | SMN1; SMN2 (0.44) | HPGDHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL11913384 | 0.85 | SMN1; SMN2 (0.37) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL1577786 | 0.85 | SMN1; SMN2 (0.37) | HPGDHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598507-B1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2017-05-31 | — | — | EP | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | ERG28, CARS1, FOLH1 | HPGD 2723/4885HTT 3768/4885SMN1; SMN2 2521/4885 |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MCL1, TP53, MYC | HPGD 583/4885HTT 3077/4885SMN1; SMN2 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.